source
- ProMis shares tumble after competitor's Alzheimer trial failure, CEO calls reaction overblownProMis Neurosciences, developer of an amyloid‑targeting Alzheimer’s therapy, saw its stock plunge sharply last week. The decline came after Acumen Pharmaceuticals announced that its own amyloid‑ta…
- Generate Biomedicines CEO touts AI-driven shrinkage of CAR-T cell engines as huge opportunityGenerate Biomedicines' chief executive highlighted a "huge opportunity" after the company applied Anthropic's Claude AI platform to make its CAR‑T cell engines smaller. The Flagship‑founded biotec…